{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:56:29Z","timestamp":1786985789358,"version":"build-2736575974"},"reference-count":109,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82100496"],"award-info":[{"award-number":["82100496"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170483"],"award-info":[{"award-number":["82170483"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.cca.2022.11.018","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T11:03:13Z","timestamp":1668682993000},"page":"113-123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Mechanisms of unusual response to lipid-lowering therapy: PCSK9 inhibition"],"prefix":"10.1016","volume":"538","author":[{"given":"Mingqi","family":"Ouyang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Die","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoquan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2022.11.018_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112519","article-title":"PCSK9 inhibitors revisited: Effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohort","volume":"146","author":"Vicente-Valor","year":"2022","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"10.1016\/j.cca.2022.11.018_b0010","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1136\/heart.89.4.451","article-title":"Lipid lowering to delay the progression of coronary artery disease","volume":"89","author":"Feher","year":"2003","journal-title":"Heart"},{"issue":"5","key":"10.1016\/j.cca.2022.11.018_b0015","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10051090","article-title":"Targeted Strategy in Lipid-Lowering Therapy","volume":"10","author":"Dayar","year":"2022","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.cca.2022.11.018_b0020","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41569-018-0107-8","article-title":"PCSK9 inhibitors: clinical evidence and implementation","volume":"16","author":"Sabatine","year":"2019","journal-title":"Nat Rev Cardiol"},{"issue":"16","key":"10.1016\/j.cca.2022.11.018_b0025","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.cca.2022.11.018_b0030","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s10557-018-6784-z","article-title":"Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials","volume":"32","author":"Bays","year":"2018","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.cca.2022.11.018_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2020.100012","article-title":"Unusual responses to PCSK9 inhibitors in a clinical cohort utilizing a structured follow-up protocol","volume":"1","author":"Warden","year":"2020","journal-title":"Am J Prev Cardiol"},{"issue":"1","key":"10.1016\/j.cca.2022.11.018_b0040","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cell.2015.01.036","article-title":"A century of cholesterol and coronaries: from plaques to genes to statins","volume":"161","author":"Goldstein","year":"2015","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.cca.2022.11.018_b0045","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/ATVBAHA.108.179564","article-title":"The LDL receptor","volume":"29","author":"Goldstein","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"5602","key":"10.1016\/j.cca.2022.11.018_b0050","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1126\/science.1078124","article-title":"Structure of the LDL receptor extracellular domain at endosomal pH","volume":"298","author":"Rudenko","year":"2002","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.cca.2022.11.018_b0055","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1161\/01.ATV.20.4.1089","article-title":"Genetic localization to chromosome 1p32 of the third locus for familial hypercholesterolemia in a Utah kindred","volume":"20","author":"Hunt","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"3","key":"10.1016\/j.cca.2022.11.018_b0060","first-page":"367","article-title":"Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin\/kexin type 9 (PCSK9)","volume":"46","author":"Cesaro","year":"2020","journal-title":"Genetics, mutations, expression, and perspective for long-term inhibition, Biofactors"},{"issue":"11","key":"10.1016\/j.cca.2022.11.018_b0065","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115880","article-title":"PCSK9 Biology and Its Role in Atherothrombosis","volume":"22","author":"Barale","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.cca.2022.11.018_b0070","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1172\/JCI29383","article-title":"Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice","volume":"116","author":"Lagace","year":"2006","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.cca.2022.11.018_b0075","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.cmet.2008.10.008","article-title":"Switch-like control of SREBP-2 transport triggered by small changes in ER cholesterol: a delicate balance","volume":"8","author":"Radhakrishnan","year":"2008","journal-title":"Cell Metab."},{"key":"10.1016\/j.cca.2022.11.018_b0080","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1476-511X-7-22","article-title":"Plasma PCSK9 levels are significantly modified by statins and fibrates in humans","volume":"7","author":"Mayne","year":"2008","journal-title":"Lipids Health Dis."},{"issue":"1","key":"10.1016\/j.cca.2022.11.018_b0085","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.atherosclerosis.2009.02.006","article-title":"Commentary PCSK9 variants: A new database","volume":"203","author":"Leigh","year":"2009","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.cca.2022.11.018_b0090","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.atherosclerosis.2011.04.018","article-title":"Clinical aspects of PCSK9","volume":"216","author":"Cariou","year":"2011","journal-title":"Atherosclerosis"},{"issue":"15","key":"10.1016\/j.cca.2022.11.018_b0095","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1073\/pnas.0501652102","article-title":"Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9","volume":"102","author":"Rashid","year":"2005","journal-title":"PNAS"},{"issue":"12","key":"10.1016\/j.cca.2022.11.018_b0100","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1161\/ATVBAHA.114.304406","article-title":"PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study","volume":"34","author":"Saavedra","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"11","key":"10.1016\/j.cca.2022.11.018_b0105","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.numecd.2011.06.002","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition","volume":"21","author":"Tibolla","year":"2011","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.cca.2022.11.018_b0110","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/978-981-15-6082-8_9","article-title":"Proprotein Convertase Subtilisin\/Kexin-Type 9 and Lipid Metabolism","volume":"1276","author":"Guo","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.cca.2022.11.018_b0115","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ahj.2022.02.008","article-title":"Trends in PCSK9 inhibitor utilization in the United States, Europe, and other countries: An analysis of international sales data","volume":"248","author":"Blais","year":"2022","journal-title":"Am Heart J"},{"key":"10.1016\/j.cca.2022.11.018_b0120","doi-asserted-by":"crossref","DOI":"10.5551\/jat.RV17065","article-title":"Advancements in the Treatment of Homozygous Familial Hypercholesterolemia","author":"Bajaj","year":"2022","journal-title":"J Atheroscler Thromb"},{"issue":"1","key":"10.1016\/j.cca.2022.11.018_b0125","doi-asserted-by":"crossref","first-page":"bvaa122","DOI":"10.1210\/jendso\/bvaa122","article-title":"Management of Familial Hypercholesterolemia: Current Status and Future Perspectives","volume":"5","author":"Lui","year":"2021","journal-title":"J Endocr Soc"},{"issue":"1","key":"10.1016\/j.cca.2022.11.018_b0130","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/jcph.766","article-title":"PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia","volume":"57","author":"Ito","year":"2017","journal-title":"J. Clin. Pharmacol."},{"issue":"23","key":"10.1016\/j.cca.2022.11.018_b0135","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","article-title":"Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab","volume":"63","author":"Koren","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.cca.2022.11.018_b0140","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijcard.2014.06.049","article-title":"Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial","volume":"176","author":"Roth","year":"2014","journal-title":"Int. J. Cardiol."},{"issue":"16","key":"10.1016\/j.cca.2022.11.018_b0145","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.cca.2022.11.018_b0150","doi-asserted-by":"crossref","first-page":"390","DOI":"10.2174\/1570161118666200807114559","article-title":"PCSK9 Inhibitors and Ezetimibe Monotherapy in Patients Not Receiving Statins: A Meta-Analysis of Randomized Trials","volume":"19","author":"Benhuri","year":"2021","journal-title":"Curr. Vasc. Pharmacol."},{"issue":"1","key":"10.1016\/j.cca.2022.11.018_b0155","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10557-019-06852-6","article-title":"Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia","volume":"33","author":"Ginsberg","year":"2019","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"3","key":"10.1016\/j.cca.2022.11.018_b0160","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.jacl.2017.03.008","article-title":"Managing the challenging homozygous familial hypercholesterolemia patient: Academic insights and practical approaches for a severe dyslipidemia, a National Lipid Association Masters Summit","volume":"11","author":"Hovingh","year":"2017","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.cca.2022.11.018_b0165","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003323","article-title":"Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin\/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies","volume":"5","author":"Rey","year":"2016","journal-title":"J. Am. Heart Assoc."},{"issue":"1","key":"10.1016\/j.cca.2022.11.018_b0170","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1194\/jlr.P088583","article-title":"The interrelations between PCSK9 metabolism and cholesterol synthesis and absorption","volume":"60","author":"Silbernagel","year":"2019","journal-title":"J. Lipid Res."},{"issue":"18","key":"10.1016\/j.cca.2022.11.018_b0175","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.cca.2022.11.018_b0180","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","article-title":"Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial","volume":"5","author":"Sabatine","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"22","key":"10.1016\/j.cca.2022.11.018_b0185","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.cca.2022.11.018_b0190","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1210\/endrev\/bnab035","article-title":"The Multifaceted Biology of PCSK9","volume":"43","author":"Seidah","year":"2022","journal-title":"Endocr. Rev."},{"issue":"18","key":"10.1016\/j.cca.2022.11.018_b0195","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1016\/j.jacc.2020.03.039","article-title":"Cognition After Lowering LDL-Cholesterol With Evolocumab","volume":"75","author":"Gencer","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.cca.2022.11.018_b0200","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.cca.2022.11.018_b0205","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jacl.2018.05.017","article-title":"Case reports of proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibition nonresponse","volume":"12","author":"Saeed","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.cca.2022.11.018_b0210","doi-asserted-by":"crossref","first-page":"e923722","DOI":"10.12659\/AJCR.923722","article-title":"Ineffective Subtilisin\/Kexin Type 9 (PCSK9) Inhibitors Monotherapy in Dyslipidemia with Low-Density Lipoprotein Cholesterol (LDL-C) Receptor Abnormalities: A Report of 2 Cases","volume":"21","author":"Matta","year":"2020","journal-title":"Am J Case Rep"},{"issue":"1","key":"10.1016\/j.cca.2022.11.018_b0215","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12944-021-01536-3","article-title":"The LDLR c.501C>A is a disease-causing variant in familial hypercholesterolemia","volume":"20","author":"Hu","year":"2021","journal-title":"Lipids Health Dis"},{"issue":"3","key":"10.1016\/j.cca.2022.11.018_b0220","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.hlc.2018.03.009","article-title":"A Small Change Can Make a Big Difference: A Lesson from Evolocumab","volume":"28","author":"Mirzaee","year":"2019","journal-title":"Heart Lung Circ"},{"issue":"1","key":"10.1016\/j.cca.2022.11.018_b0225","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jamacardio.2018.4178","article-title":"Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data","volume":"4","author":"Qamar","year":"2019","journal-title":"JAMA Cardiol."},{"issue":"2","key":"10.1016\/j.cca.2022.11.018_b0230","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2217\/fca.13.107","article-title":"Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibody","volume":"10","author":"Roth","year":"2014","journal-title":"Future Cardiol."},{"issue":"5","key":"10.1016\/j.cca.2022.11.018_b0235","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1586\/14779072.2015.1030395","article-title":"Evolocumab (AMG 145) for primary hypercholesterolemia","volume":"13","author":"Langslet","year":"2015","journal-title":"Expert Rev. Cardiovasc. Ther."},{"issue":"12","key":"10.1016\/j.cca.2022.11.018_b0240","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1586\/14779072.2015.1111759","article-title":"An evaluation of alirocumab for the treatment of hypercholesterolemia","volume":"13","author":"Farnier","year":"2015","journal-title":"Expert Rev. Cardiovasc. Ther."},{"issue":"6","key":"10.1016\/j.cca.2022.11.018_b0245","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jacl.2019.10.004","article-title":"Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses","volume":"13","author":"Robinson","year":"2019","journal-title":"J. Clin. Lipidol."},{"issue":"3","key":"10.1016\/j.cca.2022.11.018_b0250","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3390\/jcm11030475","article-title":"The Impact of the COVID-19 Outbreak on Patients\u2019 Adherence to PCSK9 Inhibitors Therapy","volume":"11","author":"Caso","year":"2022","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.cca.2022.11.018_b0255","doi-asserted-by":"crossref","first-page":"285","DOI":"10.5114\/aoms\/143476","article-title":"Treatment adherence and effect of concurrent statin intensity on the efficacy and safety of alirocumab in a real-life setting: results from ODYSSEY APPRISE","volume":"18","author":"Banach","year":"2022","journal-title":"Arch Med Sci"},{"issue":"9","key":"10.1016\/j.cca.2022.11.018_b0260","doi-asserted-by":"crossref","first-page":"895","DOI":"10.5551\/jat.RV17012","article-title":"Lipid Lowering Therapy and Circulating PCSK9 Concentration","volume":"24","author":"Nozue","year":"2017","journal-title":"J Atheroscler Thromb"},{"issue":"9","key":"10.1016\/j.cca.2022.11.018_b0265","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1194\/jlr.M008144","article-title":"High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol","volume":"51","author":"Welder","year":"2010","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.cca.2022.11.018_b0270","doi-asserted-by":"crossref","first-page":"9613","DOI":"10.1038\/s41598-017-10110-w","article-title":"Effective method for drug injection into subcutaneous tissue","volume":"7","author":"Kim","year":"2017","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.cca.2022.11.018_b0275","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/jps.20178","article-title":"Antibody pharmacokinetics and pharmacodynamics","volume":"93","author":"Lobo","year":"2004","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.cca.2022.11.018_b0280","doi-asserted-by":"crossref","first-page":"130s","DOI":"10.18433\/jpps30028","article-title":"Understanding the Monoclonal Antibody Disposition after Subcutaneous Administration using a Minimal Physiologically based Pharmacokinetic Model","volume":"21","author":"Varkhede","year":"2018","journal-title":"Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques"},{"issue":"9","key":"10.1016\/j.cca.2022.11.018_b0285","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/j.xphs.2017.03.038","article-title":"Physiologically Based Pharmacokinetic Modeling of Therapeutic Proteins","volume":"106","author":"Wong","year":"2017","journal-title":"J. Pharm. Sci."},{"issue":"12","key":"10.1016\/j.cca.2022.11.018_b0290","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1080\/17425255.2020.1828343","article-title":"An update on PCSK9 inhibitors- pharmacokinetics, drug interactions, and toxicity","volume":"16","author":"Mosteoru","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"22","key":"10.1016\/j.cca.2022.11.018_b0295","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1161\/CIRCULATIONAHA.113.002033","article-title":"Evolution and emergence of therapeutic monoclonal antibodies: what cardiologists need to know","volume":"127","author":"Foltz","year":"2013","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.cca.2022.11.018_b0300","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa1614062","article-title":"Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.cca.2022.11.018_b0305","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMc1616623","article-title":"Antidrug Antibodies in Patients Treated with Alirocumab","volume":"376","author":"Roth","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.cca.2022.11.018_b0310","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jacc.2019.12.020","article-title":"Long-Term Evolocumab in Patients With Familial Hypercholesterolemia","volume":"75","author":"Santos","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.cca.2022.11.018_b0315","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11883-021-00972-x","article-title":"Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors","volume":"23","author":"Pirillo","year":"2021","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.cca.2022.11.018_b0320","unstructured":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk, Atherosclerosis 290 (2019) 140-205."},{"issue":"9965","key":"10.1016\/j.cca.2022.11.018_b0325","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet (London, England)"},{"issue":"1","key":"10.1016\/j.cca.2022.11.018_b0330","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jacl.2018.11.007","article-title":"Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial","volume":"13","author":"Dufour","year":"2019","journal-title":"J. Clin. Lipidol."},{"issue":"6","key":"10.1016\/j.cca.2022.11.018_b0335","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.jacl.2017.08.016","article-title":"Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia","volume":"11","author":"Defesche","year":"2017","journal-title":"J. Clin. Lipidol."},{"issue":"2","key":"10.1016\/j.cca.2022.11.018_b0340","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jacc.2020.05.027","article-title":"Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia: The ODYSSEY HoFH Trial","volume":"76","author":"Blom","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.cca.2022.11.018_b0345","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S2213-8587(17)30044-X","article-title":"Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study","volume":"5","author":"Raal","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"9965","key":"10.1016\/j.cca.2022.11.018_b0350","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet (London, England)"},{"issue":"19","key":"10.1016\/j.cca.2022.11.018_b0355","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1161\/CIRCULATIONAHA.113.004678","article-title":"Effect of the proprotein convertase subtilisin\/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia","volume":"128","author":"Stein","year":"2013","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.cca.2022.11.018_b0360","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1161\/ATVBAHA.117.310217","article-title":"Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab","volume":"38","author":"Thedrez","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.cca.2022.11.018_b0365","doi-asserted-by":"crossref","DOI":"10.3390\/metabo12030256","article-title":"Insight into the Evolving Role of PCSK9","volume":"12","author":"Maliglowka","year":"2022","journal-title":"Metabolites"},{"key":"10.1016\/j.cca.2022.11.018_b0370","doi-asserted-by":"crossref","unstructured":"D. Piper, S. Jackson, Q. Liu, W. Romanow, S. Shetterly, S. Thibault, B. Shan, N. Walker, The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol, Structure (London, England : 1993) 15(5) (2007) 545-52.","DOI":"10.1016\/j.str.2007.04.004"},{"issue":"17","key":"10.1016\/j.cca.2022.11.018_b0375","doi-asserted-by":"crossref","first-page":"12882","DOI":"10.1074\/jbc.M110.113035","article-title":"A proprotein convertase subtilisin-like\/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake","volume":"285","author":"Ni","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.cca.2022.11.018_b0380","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.jacl.2019.10.007","article-title":"Pharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with proprotein convertase subtilisin\/kexin type 9 gain-of-function or apolipoprotein B loss-of-function mutations","volume":"13","author":"Hopkins","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.cca.2022.11.018_b0385","article-title":"Association of PCSK9 Variants With the Risk of Atherosclerotic Cardiovascular Disease and Variable Responses to PCSK9 Inhibitor Therapy","volume":"101043","author":"Krittanawong","year":"2021","journal-title":"Curr Probl Cardiol"},{"issue":"1","key":"10.1016\/j.cca.2022.11.018_b0390","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/clinchem\/hvaa247","article-title":"Lipoprotein(a) and Cardiovascular Disease","volume":"67","author":"Kamstrup","year":"2021","journal-title":"Clin. Chem."},{"issue":"8","key":"10.1016\/j.cca.2022.11.018_b0395","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1177\/2047487320915803","article-title":"Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: A pooled analysis from 10 ODYSSEY Phase 3 studies","volume":"28","author":"Mahmood","year":"2021","journal-title":"Eur J Prev Cardiol"},{"issue":"3","key":"10.1016\/j.cca.2022.11.018_b0400","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.tcm.2019.05.007","article-title":"The PCSK9 revolution: Current status, controversies, and future directions","volume":"30","author":"Warden","year":"2020","journal-title":"Trends Cardiovasc. Med."},{"issue":"14","key":"10.1016\/j.cca.2022.11.018_b0405","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.jacc.2021.07.056","article-title":"Hepatic Sensing Loop Regulates PCSK9 Secretion in Response to Inhibitory Antibodies","volume":"78","author":"Oleaga","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.cca.2022.11.018_b0410","doi-asserted-by":"crossref","first-page":"376","DOI":"10.7326\/M17-2485","article-title":"Diagnosing Resistance to a Proprotein Convertase Subtilisin\/Kexin Type 9 Inhibitor","volume":"168","author":"Shapiro","year":"2018","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.cca.2022.11.018_b0415","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jacl.2015.11.011","article-title":"LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design","volume":"10","author":"Blom","year":"2016","journal-title":"J. Clin. Lipidol."},{"issue":"2","key":"10.1016\/j.cca.2022.11.018_b0420","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa061189","article-title":"Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia","volume":"356","author":"Cuchel","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.cca.2022.11.018_b0425","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.2174\/0929867326666190121120735","article-title":"Therapeutic Options for Homozygous Familial Hypercholesterolemia: The Role of Lomitapide","volume":"27","author":"Giammanco","year":"2020","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.cca.2022.11.018_b0430","first-page":"40","volume":"381","author":"Cuchel","year":"2013","journal-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study, Lancet"},{"issue":"3","key":"10.1016\/j.cca.2022.11.018_b0435","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1161\/CIRCULATIONAHA.117.028208","article-title":"Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia","volume":"136","author":"Blom","year":"2017","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.cca.2022.11.018_b0440","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jacl.2020.08.006","article-title":"Long-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia: Five-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER)","volume":"14","author":"Underberg","year":"2020","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.cca.2022.11.018_b0445","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1042\/bj2720181","article-title":"The effect of (-)-hydroxycitrate on the activity of the low-density-lipoprotein receptor and 3-hydroxy-3-methylglutaryl-CoA reductase levels in the human hepatoma cell line Hep G2","volume":"272","author":"Berkhout","year":"1990","journal-title":"Biochem. J."},{"key":"10.1016\/j.cca.2022.11.018_b0450","doi-asserted-by":"crossref","DOI":"10.1007\/s11883-022-01036-4","article-title":"Major Concepts in Treatment with Bempedoic Acid and Inclisiran that Clinicians Need To Know","author":"Parham","year":"2022","journal-title":"Curr Atheroscler Rep"},{"issue":"11","key":"10.1016\/j.cca.2022.11.018_b0455","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.cca.2022.11.018_b0460","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial","volume":"322","author":"Goldberg","year":"2019","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.cca.2022.11.018_b0465","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/2047487319864671","article-title":"Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy","volume":"27","author":"Ballantyne","year":"2020","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"2","key":"10.1016\/j.cca.2022.11.018_b0470","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/14656566.2018.1550071","article-title":"Mipomersen and its use in familial hypercholesterolemia","volume":"20","author":"Parham","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.cca.2022.11.018_b0475","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform","volume":"50","author":"Bennett","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"9719","key":"10.1016\/j.cca.2022.11.018_b0480","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet (London, England)"},{"issue":"19","key":"10.1016\/j.cca.2022.11.018_b0485","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1161\/CIRCULATIONAHA.112.104125","article-title":"Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease","volume":"126","author":"Stein","year":"2012","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.cca.2022.11.018_b0490","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.jacc.2013.07.081","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Thomas","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.cca.2022.11.018_b0495","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s12020-015-0838-9","article-title":"The role of ANGPTL3 in controlling lipoprotein metabolism","volume":"52","author":"Tikka","year":"2016","journal-title":"Endocrine"},{"issue":"23","key":"10.1016\/j.cca.2022.11.018_b0500","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1002926","article-title":"Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia","volume":"363","author":"Musunuru","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.cca.2022.11.018_b0505","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.cca.2022.11.018_b0510","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","article-title":"ANGPTL3 Deficiency and Protection Against Coronary Artery Disease","volume":"69","author":"Stitziel","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.cca.2022.11.018_b0515","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJMc1705994","article-title":"ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia","volume":"377","author":"Gaudet","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2022.11.018_b0520","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.atherosclerosis.2017.08.031","article-title":"Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol","volume":"268","author":"Xu","year":"2018","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.cca.2022.11.018_b0525","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1161\/ATVBAHA.120.315204","article-title":"ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia-Brief Report","volume":"41","author":"Reeskamp","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"24","key":"10.1016\/j.cca.2022.11.018_b0530","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","article-title":"Evinacumab in Patients with Refractory Hypercholesterolemia","volume":"383","author":"Rosenson","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.cca.2022.11.018_b0535","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for Homozygous Familial Hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.cca.2022.11.018_b0540","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.cell.2019.10.034","article-title":"GPR146 Deficiency Protects against Hypercholesterolemia and Atherosclerosis","volume":"179","author":"Yu","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.cca.2022.11.018_b0545","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-022-05006-3","article-title":"Inhibition of ASGR1 decreases lipid levels by promoting cholesterol excretion","author":"Wang","year":"2022","journal-title":"Nature"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898122013857?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898122013857?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:08:34Z","timestamp":1757862514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898122013857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":109,"alternative-id":["S0009898122013857"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2022.11.018","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms of unusual response to lipid-lowering therapy: PCSK9 inhibition","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2022.11.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}